Simcere Zaiming Presents 9 Studies at the 2026 ASCO Annual Meeting

Simcere Zaiming’s Pan-RAS Inhibitor SIM0532 Doses First Patient in Clinical Trial

Simcere Zaiming’s LRRC15-Targeting ADC SIM0613 Receives IND Approval in China

FDA Granted Fast Track Designation for SIM0505 (CDH6 ADC) for the Treatment of Ovarian Cancer

Rademikibart Phase III Data Presented as Late-Breaking Oral at AAD Annual Meeting

Phase I/II NMBIC Data of SIM0237 Releases as Oral presentation at the 2026 EAU26

Deuremidevir Hydrobromide Dry Suspension Doses First Patient in Phase 3 Clinical Trial for RSV Infection

Novel Anti-Stroke Candidate SIM0811 Doses First Participant in Phase I Clinical Trial

Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease

Simcere Zaiming's a Bispecific ADC SIM0610 Doses First Patient in a Phase I Clinical Trial